Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Cinemark Holdings

HCI Group

Las Vegas Sands

It's time to cut ties with toxic stocks including CNK, LVS, TNDM and HCI to safeguard your portfolio.

Distance Yourself From These 4 Toxic Stocks to Ward Off Losses

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #Freedom2Bolus--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that t:slim X2 insulin pump users have delivered more than 1 million insulin boluses using the t:connect app feature on their personal mobile device in the first month following its commercial release. “The rapid adoption of our mobile bolus feature demonstrates the importance of our offering new technologies that provide lifestyle benefits, in additi

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:connect Mobile App

Credit Suisse

Heska

Zalando SE

Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio.

5 Toxic Stocks That May Prove Hazardous for Your Portfolio

The diabetes specialist's Q2 financial report isn't sitting well with investors.

Why Tandem Diabetes Care Stock Is Cratering Today

Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.

Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Brian Hansen - EVP & Chief Commercial Officer Leigh Vosseller - EVP, CFO & Treasurer Conference Call Participants Steven Lichtman - Oppenheimer Brooks O'Neil - Lake Street Capital Markets Travis Steed - Bank of America Merrill Lynch Jayson Bedford - Raymond James & Associates Matthew O'Brien - Piper Sandler & Co. Christopher Pasquale - Nephron Research Dane Reinhardt - Robert W. Baird & Co. Operator Thank you for standing by, and welcome to Tandem's Second Quarter 2022 Earnings Conference Call.

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2022 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2022 and updated its financial guidance for the year ending December 31, 2022. Second Quarter 2022 Financial Highlights Compared to Second Quarter 2021: Worldwide installed base increased 40 percent to more than 375,000 customers. Sales in the United States increased 14 percent to $145.7 million. Ren

Tandem Diabetes Care Announces Second Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its acquisition of infusion set developer, Capillary Biomedical. “Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” said John Sheridan, Tandem Diabetes Care president and chief ex

Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2022 results after the financial markets close on Wednesday, August 3, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2022 financial and operating results. A live webcast of the call will be available on Tandem Dia

Tandem Diabetes Care to Announce Second Quarter 2022 Financial Results on August 3, 2022

TNDM revenue continues to grow as the company increases market share in an expanding industry. Mixed Q4 2021 and Q1 2022 earnings, coupled with the overall market downturn, have created an extremely low valuation relative to its high-growth peers.

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes

Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails

Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.

Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now

Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the appointments of Myoung Cha and Joao Malagueira as independent members of its board of directors effective June 15, 2022. “We welcome Joao and Myoung to our Board of Directors at this exciting stage in Tandem's evolution,” said John Sheridan, president and CEO, Tandem Diabetes Care. “Joao's extensive international experience brings tremendous value

Tandem Diabetes Care Welcomes Two New Members to Board of Directors

DexCom

These diabetes specialists are down but not out.

2 Beaten-Down Stocks With 80% to 113% Upside, According to Wall Street

Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.

Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data

NEW ORLEANS--(BUSINESS WIRE)---- $TNDM #TNDM--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with Control-IQ® technology. The data was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. “Our Control-IQ technology continues to be a great equalizer for people with insulin-i

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock?

Why Is Tandem Diabetes Care, Inc. (TNDM) Down 16.3% Since Last Earnings Report?

Celsius Holdings

Innovative Industrial Properties

ServiceNow

NVIDIA

OptimizeRx Corp

Paylocity Hlds

PDC Energy Inc

SolarEdge Technologies

STAAR Surgical

Except for energy stocks, 2022 has been a very difficult year to find any equities able to perform well in these volatile markets. And high-growth stocks have been hit especially hard.

The 10 Best High-Growth Stocks to Buy

Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022 at 11:00am Eastern Time (8:00am Pacific Time). The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabe

Tandem Diabetes Care Announces Upcoming Virtual Conference Presentation

Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.

Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Susan Morrison - EVP and Chief Administrative Officer John Sheridan - President and Chief Executive Officer Leigh Vosseller - EVP and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer & Co Brooks O'Neil - Lake Street Capital Alex Nowak - Craig-Hallum Capital Jayson Bedford - Raymond James Danielle Antalffy - SVB Securities Jeff Johnson - Baird Operator 00:04 Thank you for standing by, and welcome to Tandem's First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2022 and updated its financial guidance for the year ending December 31, 2022. First Quarter Financial Highlights: First quarter 2022 sales increased 25 percent to $175.9 million compared to the same period of 2021. Worldwide pump shipments increased 11 percent to 28,095 pumps compared to th

News for Tandem Diabetes Care Stock (TNDM)